New evidence-based A1, A2, A3 alarm time zones for transferring thrombolysed patients to hyper-acute stroke units:faster is better by Han, Thang S. et al.
                          Han, T. S., Gulli, G., Affley, B., Fluck, D., Fry, C. H., Barrett, C., ... Sharma,
P. (2019). New evidence-based A1, A2, A3 alarm time zones for transferring
thrombolysed patients to hyper-acute stroke units: faster is better.
Neurological Sciences, 40(8), 1659-1665. https://doi.org/10.1007/s10072-
019-03901-8
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1007/s10072-019-03901-8
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Springer Nature at
https://link.springer.com/article/10.1007%2Fs10072-019-03901-8. Please refer to any applicable terms of use of
the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
ORIGINAL ARTICLE
New evidence-based A1, A2, A3 alarm time zones for transferring
thrombolysed patients to hyper-acute stroke units: faster is better
Thang S. Han1 & Giosue Gulli2 & Brendan Affley2 & David Fluck3 & Christopher H. Fry4 & Christopher Barrett5 &
Puneet Kakar6 & Sapna Sharma1 & Pankaj Sharma1,7
Received: 31 January 2019 /Accepted: 12 April 2019
# The Author(s) 2019
Abstract
Objectives The National Institute of Health and Clinical Excellence and The Royal College of Physicians recommend transferring
thrombolysed patients with stroke to a hyperacute stroke unit (HASU) within 4 h from hospital arrival (TArrival-HASU), but there is
paucity of evidence to support this cut-off. We assessed if a shorter interval within this target threshold conferred a significant
improvement in patient mortality.
Design We conducted a retrospective analysis of prospectively collected data from the Sentinel Stroke National Audit Programme.
Setting Four major UK hyperacute stroke centres between 2014 and 2016.
Participants A total of 183 men (median age = 75 years, IQR = 66–83) and 169 women (median age = 81 years, IQR = 72.5–88)
admitted with acute ischaemic stroke.
Main outcomemeasures We evaluated TArrival-HASU in relation to inpatient mortality, adjusted for age, sex, co-morbidities, stroke
severity, time between procedures, time and day on arrival.
Results There were 51 (14.5%) inpatient deaths. On ROC analysis, the AUC (area under the curve) was 61.1% (52.9–69.4%, p =
0.01) and the cut-off of TArrival-HASU where sensitivity equalled specificity was 2 h/15 min (intermediate range = 30 min to 3 h/
15 min) for predicting mortality. On logistic regression, compared with the fastest TArrival-HASU group within 2 h/15 min, the
slowest TArrival-HASU group beyond upper limit of intermediate range (≥ 3 h/15 min) had an increased risk of mortality: 5.6% vs.
19.6%, adjusted OR = 5.6 (95%CI:1.5–20.6, p = 0.010).
Conclusions We propose three new alarm time zones (A1, A2 and A3) to improve stroke survival: BA1 Zone^ (TArrival-HASU <
2 h/15 min) indicates that a desirable target, BA2 Zone^ (TArrival-HASU = 2 h/15 min to 3 h/15 min), indicates increasing risk and
should not delay any further, and BA3 Zone^ (TArrival-HASU ≥ 3 h/15 min) indicates high risk and should be avoided.
Keywords Evidence-basedmedicine . ROC analysis . Ischaemic stroke . Thrombolysis . tPA . Stroke units
Introduction
Thrombolysis is an effective treatment for acute ischaemic
stroke [1] and is widely performed in hyperacute stroke units
(HASUs) [2, 3]. Door to needle time has been a major focus of
research [4, 5], but the time taken to transfer patients from
hospital arrival to HASU is less studied and indeed may be
as important. The National Institute of Health and Clinical
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Excellence (NICE) [6] and Royal College of Physicians
(RCP) recommend patients presenting with an acute stroke
to be transferred to a HASU within 4 h from hospital arrival
(TArrival-HASU) [7]. This time window covers the time taken
from the point at which the patient arrives hospital to brain
imaging, then to intravenous thrombolysis, and followed by
the transfer to HASU; thus, TArrival-HASU partly depends on the
speed at which the patient receives brain imaging and
thrombolysis.
The TArrival-HASU span of 4 h is relatively long but is related
to the time needed to administer recombinant tissue plasmin-
ogen activator (rtPA). Some centres provide thrombolysis
within the CT scanning unit to minimise delay while others
may return the patient to the Emergency department or send to
HASU for such an intervention [7].
In this study, we attempted to determine whether a more
detailed subset of TArrival-HASU could be derived within the
recommended target threshold of 4 h among patients under-
going thrombolysis for acute ischaemic stroke. This should
provide an evidence-based target time for TArrival-HASU in the
management of these patients.
Methods
Study design, participants and setting
We conducted a retrospective analysis of prospectively col-
lected data from the Sentinel Stroke National Audit
Programme (SSNAP) which is the national register of stroke
care, comprising clinical characteristics and care quality of
patients admitted to acute care hospitals in England and
Wales [8]. The data were collected prospectively from the time
of admission up to 6 months after stroke in patients admitted
to four major UK hyperacute stroke centres in Surrey County
between January 2014 and February 2016 [9, 10]. In order to
test our objectives against the 4-h transfer target from the point
of arrival to HASU set out by NICE [6] and RCP [7] for
thrombolysed patients, the present study selected only those
who were thrombolysed.
HASUs are located in each of the four study centres, pro-
viding HASU management but not endovascular services.
Patients eligible for endovascular thrombolysis started intra-
venous thrombolysis locally and were then transferred to the
regional tertiary centre, after discussionwith the interventional
neuroradiologists, for endovascular treatment. The SSNAP
database does not collect information on patients receiving
endovascular treatment in the tertiary centre. Audits at the
time of data collection showed < 10% of patients were referred
for endovascular treatment. Thus, patients with large artery
occlusion, and not eligible for endovascular treatment, were
included in this study. Because patients who had endovascular
treatment were not included in this study, results refer only to
patients who had intravenous treatment.
SSNAP has approval from the Confidentiality Advisory
Group of the Health Research Authority to collect patient data
under section 251 of the National Health Service Act 2006.
No additional ethical approval was sought [9, 10].
Socio-demographic factors and medical history
Demographic data were collected and documented by stroke
consultants and stroke nurse specialists including age at arriv-
al, gender, past medical history (atrial fibrillation, hyperten-
sion, congestive heart failure, diabetes mellitus, previous
stroke and drug history) and time points from onset of symp-
toms to hospital arrival, brain imaging, thrombolysis and
transfer times to HASU. In addition, details of new cases of
urinary tract infection and pneumonia acquired in hospital
within 7 days of admission were documented.
Stroke diagnosis and severity
Stroke was diagnosed based on clinical presentation and brain
imaging. The severity of stroke symptoms at arrival and 24 h
post-thrombolysis was assessed by the National Institutes of
Health for Stroke Scale (NIHSS) with a score range from no
symptoms to severe stroke symptoms (NIHSS score = 0 to 42).
Disability and mortality
Degree of disability or dependence with daily activities was
assessed by a modified Rankin Scale (mRS), ranging from no
symptoms to severe symptoms (mRS score = 0 to 5) and mor-
tality (mRS score = 6).
Thrombolysis
Thrombolysis using the fibrinolytic agent alteplase (rtPA) was
considered for patients who fulfilled criteria for treatment in-
cluding time from onset, confirmed diagnosis of ischaemic
stroke and without contra-indications.
Categorisation of variables
Dichotomisation was applied for hypertension, congestive
heart failure, atrial fibrillation, diabetes and inpatient mortality
according to the presence or absence of history of the condi-
tion. Moderately severe to severe stroke on arrival or 24 h
post-thrombolysis was defined as a NIHSS score ≥ 16 and
moderately severe to severe disability on discharge for those
with mRS score = 4 and 5.
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Statistical analysis
We initially performed receiver operating characteristic
(ROC) curve analysis to determine (1) the association
of TArrival-HASU with mortality as indicated by area under
the curve (AUC) and (2) the cut-offs of TArrival-HASU (d0)
where sensitivity equals specificity for identifying mor-
tality using the two-graph ROC plot technique [11, 12];
d0 was identified by interpolating from the intersection
where sensitivity equals specificity (θ0) and limits of
intermediate range (IR) from the point where sensitivity
(lower limit) and specificity (upper limit) equal 95%. We
then conducted multivariable logistic regression analysis
to estimate the risk of inpatient mortality (dependent var-
iable) from slower TArrival-HASU (above the d0 and above
upper limit of IR) compared with the referent group of
hyper-fast TArrival-HASU within d0 (predictive variables).
The results were presented in four models; model 1: un-
adjusted, model 2: adjusted for age, sex and co-morbid-
ities, model 3: additional adjustment to model 2 for
stroke severity on arrival, time from symptom onset to
hospital arrival (door time), from arrival to brain imaging
and from arrival to thrombolysis (door to needle), and
model 4: additional adjustment to model 3 for time of
day and day of week on arrival. Results are expressed in
odds ratios (OR) and 95% confidence intervals (CI).
Most variables had no missing data, which were handled
in analysis using a ‘listwise deletion of missing data’
approach [13]. Analyses were performed using SPSS
V.23.0 (SPSS Inc., Chicago, Illinois, USA). The null hy-
pothesis was rejected when p < 0.05.
Results
Of the 3309 patients collected in the database, 2758 (83.3%)
patients presented with ischaemic stroke; of the remainder 518
(15.7%) patients had a haemorrhagic stroke and 33 (1.0%)
were unspecified. Among patients with ischaemic stroke,
431 (15.6%) underwent thrombolysis, in whom 352 (183
men and 169 women) achieved the TArrival-HASU target within
4 h; these patients were selected for analysis in relation to
inpatient mortality (Fig. 1).
Median and interquartile range (IQR) age was 75 (66–83)
years inmen and 81 (72.5–88) years in women. Themedian time
from symptom onset to hospital arrival was 1 h/9 min (50 min to
1 h/39 min), arrival to brain imaging was 19 min (13–28 min),
arrival to thrombolysis was 50 min (34 min to 1 h/8 min) and
TArrival-HASU was 3 h/00 min (2 h/22 min to 3 h/36 min). In total,
there were 51 (14.5%) inpatient deaths (Table 1).
ROC curve analysis showed that AUC for predicting inpatient
mortality was 61% (95%CI: 53–69%, p= 0.011) (Fig. 2). The
two-graph ROC plot revealed that the d0 for identifying inpatient
mortality was 2 h/15 min (IR = 30 min to 3 h/15 min) (Fig. 3).
Three categories of patients based on these findings were created
for further assessment with inpatient mortality by logistic regres-
sion; hyper-fast group: 71 (20.2%) patients with TArrival-HASU
within d0 (< 2 h/15 min), intermediate group: 143 (40.6%) pa-
tients with TArrival-HASU between d0 and upper limit IR (2 h/
15 min to 3 h/15 min), and slow group: 138 (39.2%) patients
with TArrival-HASU above upper limit of IR (≥ 3 h/15 min).
Increasing TArrival-HASU was associated with increasing
proportions of inpatient mortality (χ2 = 7.4, p = 0.007):
hyper-fast group = 5.6%, intermediate group = 14.0% and
Total (n=3309)
83.3% ischaemic stroke (n=2758)
15.7% haemorrhagic stroke (n=518)
1% unspecified (n=33)
Ischaemic stroke onset 
in the community: 
n=2532
Ischaemic stroke onset 
in hospital: n=226
TRANSFERRED TO 
HASU WITHIN 4h: 
n=352 (81.7%)
Thrombolysed: n=431
Not thrombolysed: 
n=2101
Transferred to HASU after 4h: n=75
Transferred to non-HASU wards: n=4
Fig. 1 Flowchart of patient cohort
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slow group = 19.6%. Compared with the hyper-fast group, the
slow group had unadjusted OR for inpatient mortality of 4.1
(95%CI:1.4–12.2). This OR increased to 4.9 (95%CI:1.4–
17.7) after adjustment for age, sex, co-morbidities, stroke se-
verity, time from symptom onset to arrival, arrival to brain
imaging and arrival to thrombolysis. Additional adjustment
for time and day on hospital arrival showed the OR increased
further to 5.6 (95%CI:1.5–20.6) (Table 2). There was a trend
in increasing ORs for those in the intermediate group com-
pared with the hyper-fast group, but was not statistically sig-
nificant. Extending TArrival-HASU for the slow group to ≥ 3 h/
30 min showed the risk of death elevated to 6.2-fold
(95%CI:1.7–23.1) (Table 3).
We found that compared with the hyper-fast group, the slow
group did not have increased risk (adjusted for age, sex, co-
morbidities, severity of stroke on arrival and time between
procedures) of hospital-acquired pneumonia (OR = 1.88,
95%CI:0.55–6.39, p = 0.315) or urinary tract infection (OR=
0.69, 95%CI:0.22–2.19, p= 0.529) within 7 days of admission,
prolonged length of stay in HASU of > 3 weeks (OR = 1.04,
95%CI:0.45–2.39, p = 0.921) or moderately severe to severe dis-
ability on discharge (OR= 1.88, 95%CI:0.71–4.96, p = 0.203).
Patients presented with moderately severe to severe stroke
on arrival were more likely to be thrombolysed earlier (adjust-
ed OR = 0.24, 95%CI:0.10–0.55). Faster thrombolysis on ar-
rival resulted in reduced proportions of patients with moder-
ately severe to severe stroke 24 h post-thrombolysis (i.e. pro-
portions of patients with moderately severe to severe stroke at
Table 1 Characteristics of 352
patients admitted with ischaemic
stroke who received thrombolysis
and transferred to HASU within
4 h on arrival
Median Interquartile range
Age of men (years) 75.0 66.0–83.0
Age of women (years) 81.0 72.5–88.0
Time between symptom onset and arrival (h/min) 1:09 0:50–1:39
Time between arrival to brain imaging (h/min) 0:19 0:13–0:28
Time between arrival to thrombolysis (h/min) 0:50 0:34–1:08
Time between arrival and transfer to HASU (h/min) 3:00 2:22–336
n Proportion (%)
Men/women 183:169 52:48
First stroke/recurrent stroke 279:73 79.3:20.7
Atrial fibrillation 70 19.9
Hypertension 192 54.5
Congestive heart failure 12 3.4
Diabetes 55 15.6
Inpatient mortality 51 14.5
Fig. 2 ROC curve for identifying inpatient mortality from different
transfer time from hospital arrival to HASU
Fig. 3 Two-graph ROC plot to identify mortality showing the cut-off of
TArrival-HASU (d0) interpolated from the point where sensitivity (●) equals
specificity (□) (θ0) and from the intermediate range (IR) at 95% level of
sensitivity and specificity (red horizontal line)
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24 h post-thrombolysis minus proportions of patients with
moderately severe to severe stroke on arrival, p = 0.003): −
13.6, − 8.3 and + 4.0% for tertile 1 (< 36 min), tertile 2 (≥
36min to 1 h/19min) and tertile 3 (≥ 1 h/19min), respectively.
Further analysis was conducted to assess mortality rates
in different tertiles of the time between thrombolysis to
HASU (i.e. eliminating the influence from the time between
arrival and brain imaging and between arrival and thrombol-
ysis). Increasing length of transfer time from thrombolysis to
HASU was associated with higher proportions of inpatient
mortality (χ2 = 9.4, p = 0.009): tertile 1 (< 1 h/45 min) =
8.2%, tertile 2 (1 h/45 min to 2 h/30 min) = 13.8% and
tertile 3 (≥ 2 h/30 min) = 22.4%. Compared with the fastest
transfer group, the slowest transfer group had increased risk
of inpatient mortality by 3.35-fold (95%CI:1.43–7.89, p =
0.006), adjusted for age, co-morbidities and stroke severity
on arrival. We found no relationship between time from
arrival to brain imaging and inpatient mortality within this
group of patients.
Discussion
The present study focused on the relationship between inpatient
mortality and rapidity of transferring patients to HASU from
hospital arrival within the recommended 4-h window among
patients receiving thrombolysis. Our findings provide evidence-
based cut-offs of transfer target below the currently recommend-
ed target byNICE andRCP of 4 h, independently of demograph-
ic factors, co-morbidities, stroke severity, time to brain imaging,
time to thrombolysis and time and day of admission.
We have identified two cut-off levels which provide three
alarm time zones to improve stroke survival: BA1 Zone^
(hyper-fast TArrival-HASU < 2 h/15min) indicates a desirable target
for transferring patients to HASU as it has low mortality risk,
BA2Zone^ (intermediate TArrival-HASU=2 h/15min to 3 h/15min)
indicates an increasing risk and should not delay any further, and
BA3 Zone^ (slow TArrival-HASU ≥ 3 h:15 min) indicates high mor-
tality risk and should be avoided. This proposal was validated by
logistic regression analysis showing that compared with the
Table 2 Comparison of inpatient mortality between patients with ischaemic stroke who were transferred from arrival to HASU at different time within
4 h (cut-offs at 2 h/15 min and 3 h/15 min)
Risk of inpatient mortality
Hyper-fast groupa
(< 2 h/15 min)
Intermediate group
(≥ 2 h/15 min to 3 h/15 min)
Slow group
(≥ 3 h/15 min)
Mortality rates 4/71 (5.6%) 20/143 (14.0%) 27/138 (19.6%)
OR OR 95% CI p OR 95% CI p
Model 1: Unadjusted 1 2.72 0.89–8.30 0.078 4.07 1.37–12.15 0.012
Model 2: Adjusted for age, sex, congestive heart failure,
hypertension, atrial fibrillation, diabetes and previous stroke
1 2.94 0.93–9.26 0.065 4.24 1.39–13.00 0.011
Model 3: Adjusted as in model 2 plus severity on arrival, time from
onset to arrival, arrival to brain imaging and arrival to thrombolysis
1 3.08 0.87–10.91 0.082 4.89 1.35–17.69 0.016
Model 4: Adjusted as in model 3 plus time and day on
hospital arrival
1 3.42 0.95–12.32 0.060 5.59 1.52–20.61 0.010
a Referent group
Table 3 Comparison of inpatient mortality between patients with ischaemic stroke who were transferred from arrival to HASU at different time within
4 h (cut-offs at 2 h/15 min and 3 h/30 min)
Risk of inpatient mortality
Hyper-fast groupa
(< 2 h/15 min)
Intermediate group
(≥ 2 h/15 min to 3 h/30 min)
Slow group
(≥ 3 h/30 min)
4/71 (5.6%) 25/172 (14.5%) 22/109 (20.2%)
Model 1: Unadjusted 1 2.85 0.95–8.51 0.061 4.24 1.39–12.88 0.011
Model 2: Adjusted for age, sex, congestive heart failure,
hypertension, atrial fibrillation, diabetes and previous stroke
1 3.28 1.00–10.75 0.050 5.46 1.63–18.31 0.006
Model 3: Adjusted as in model 2 plus severity on arrival, time from
onset to arrival, arrival to brain imaging and arrival to thrombolysis
1 3.67 1.08–12.46 0.037 6.38 1.78–22.86 0.004
Model 4: Adjusted as in model 3 plus time and day on
hospital arrival
1 4.03 1.15–14.19 0.030 6.24 1.68–23.12 0.006
a Referent group
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hyper-fast group in the BA1 Zone^, the slow group in the BA3
Zone^ had a 5.6-fold greater adjusted risk of inpatient mortality.
We found that among the 138 patients (39.2% of the study sam-
ple) in the BA3 Zone^, there were 27 deaths (52.9% of total
mortality), compared with only 4 deaths (7.8%) among the 71
patients in the BA1 Zone^. Our findings therefore provide strong
support for the use of these time zones.
There exists a number of service standards set by authoritative
bodies including NICE [6] and RCP [7] with respect to the acute
stroke pathway; these include the time from symptom onset to
hospital admission, followed by brain imaging, thrombolysis and
transfer to HASU. The recommended 4-h window has been
adopted for number of years without modification despite rapid
advances in hyperacute stroke service have been achieved in
recent years [3]. Brain imaging is now operating continuously
24 h every daywith the proportions of patients receiving CTscan
within 1 h of hospital arrival rose from 41% in 2013 to 51% in
2016 [8]. Over this 3-year period, Bdoor to needle^ time has
progressively been quickened by 2 min 20 s a year [8].
Integrated network linking the community and specialist stroke
centres has been firmly established [2]. National audits such as
SSNAP provide continuous updated stroke service performance
and recommendations [8]. The 4-h TArrival-HASU target therefore
may be outdated and a new evidence-based cut-off should now
be considered. Further studies are suggested to examine other
standards such as time to transfer from the point of thrombolysis
to HASU to provide an optimal evidence-based target. The pres-
ent study did not examine those factors that influence actual
TArrival-HASU times and this is the next step that are practical at
both local and regional/national levels. Examples can include,
minimising out-of-hours and weekend effects by ensuring that
the right capacity remains available to allow seamless flow of
patients through the pathway to increase patient throughput and
avoid delayed transfer of care.
Additional analysis found that rapid TArrival-HASU did not
significantly associate with a number of adverse outcomes
(nosocomial infections within 7 days of admission, prolonged
hospital stay or disability on discharge) suggesting that early
transfer to HASU not only lowers the rates of mortality but
also has no other detrimental effects to the patients. Thus,
rapid transfer to HASU provides favourable outcomes to pa-
tients treated with thrombolysis for acute stroke. This may in
part be explained by a number of benefits gained from faster
transfer to HASU including early review from hyperacute
stroke specialists and supportive care such as dysphagia
screen and appropriate nutrition, which has been shown to
associate with better outcomes [9]. We have calculated that
dysphagia screen in hyper-fast group was performed within
4 h of admission in 97.2%, between 4 and 72 h in 2.8% and
0% beyond 72 h; in comparison, the corresponding figures for
the slow group were 89.9%, 8.0% and 2.2% (χ2 = 12.6, p =
0.007). It should be borne in mind, however, that establishing
an ‘optimal’ TArrival-HASU requires consideration of a number
of factors including stability of the patients and trade-offs
between benefits and risks in terms of financial costs to ac-
commodate HASU service and safety of the patients when
varying the desired true positive rate (sensitivity) and against
false positive rate (1-specificity).
Evidence from previous studies has indicated that the earlier is
thrombolysis, the greater the likelihood for good stroke outcomes
[14, 15]. However, little is known about how stroke severity
influences the likelihood of receiving interventions [16]. In this
study, we observed that patients with more severe stroke on
arrival, indicated by NIHSS score, were more likely to be
thrombolysed at earlier times, although they were not necessarily
transferred to HASU earlier. Time to stabilise the patient or avail-
ability of HASU beds may in part explain this discrepancy.
Previous analysis of SSNAP data has found that admission to
HASU within 4 h varied with days of the week and there was a
variation in mortality with time of the day but this association
was not apparent between days of the week in which patients
were admitted [17, 18]. Our study found that adjustment for time
and day on arrival slightly accentuated the relationship between
TArrival-HASU and mortality, as reflected by an increase in the OR.
Strengths and limitations
The strengths in the present study lie in their completeness of
data including a number of variables, such as time to brain im-
aging and thrombolysis, which could potentially confound the
associations between TArrival-HASU andmortality. Various cut-offs
of TArrival-HASU could be derived by the powerful two-graph
ROC analysis [11, 12] for further examination by logistic regres-
sion. Our conclusions are robustly supported by logistic regres-
sion analysis where potential confounders were simultaneously
adjusted using multivariate modelling as well as further analysis
from the point of thrombolysis to HASU. This eliminates the
variable periods prior to thrombolysis such time from hospital
arrival to brain imaging or from arrival to thrombolysis. We have
also extended our analysis to include patients who did not meet
the 4-h target of transfer from hospital arrival to HASU and
showed that the risk of mortality were similarly elevated among
the slowest transfer group. We also explored other cut-offs for
TArrival-HASU including the use of tertiles or limits of IR where
sensitivity (lower limit) and specificity (upper limit) were at 90%
and found similar, but weaker, patterns in the prediction of inpa-
tient mortality. The present study is limited by its subjects who
were restricted to four centres. However, this study population
has similar characteristics to those in England and Wales [8] but
caution should, however, be taken to extrapolate our findings.
The overall mortality rate among patients treated with thrombol-
ysis in the present study (including those who were transferred to
HASU beyond 4 h) was 14.8% (64/431) which is lower than the
reported figure of 19.4% from a recent meta-analysis of 27 stud-
ies [19]. We focused on BTArrival-HASU^, which is as relevant as
Bdoor to needle time^ or Bthrombolysis to HASU^ time. It is
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likely that the outcomes would be similar for these three mea-
sures as their journeys are dependent on each other. The reason
that we selected TArrival-HASU is that there is a clear recommended
4-h target transfer window set out by NICE [6] and RCP [7] with
which we could compare.
Another limitation of the present study is that, due to the
inherent design of SSNAP, other features were not collected that
could be associated with clinical outcome in thrombolysed pa-
tients, e.g. altered level of consciousness, symptomatic intracra-
nial haemorrhage, presence of large vessel occlusion and site of
occlusion. In addition, there is a lack of information about hy-
peracute complications such as severe hypertension, acute angio-
edema, hyperacute haemorrhage or subtypes of ischaemic stroke
that would be useful for a better understanding of the reasons for
increased TArrival-HASU.
In conclusion, TArrival-HASU below the recommended target
window of 4 h associates with lower inpatient mortality. We
propose three new alarm time zones to improve stroke survival:
BA1 Zone^ (TArrival-HASU < 2 h/15 min) indicates a desirable tar-
get for transferring patients to HASU, BA2 Zone^ (TArrival-
HASU=2 h/15 min to 3 h/15 min) indicates an increasing risk
and should not delay any further, and BA3 Zone^ (TArrival-
HASU ≥ 3 h/15 min) indicates high risk and should be avoided.
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